Search for a doctor

Sahil Khanna, M.B.B.S., M.S.

  1. Gastroenterologist
Request an Appointment

Publications

  1. Tariq R, Dilmaghani S, Advani R, Soroush A, Berzin T, Khanna S. Perception and Understanding of Artificial Intelligence Among Gastroenterology Fellows and Early Career Gastroenterologists: A Nationwide Cross-Sectional Survey Study. Dig Dis Sci. 2025 Apr 24 [Epub ahead of print]
    View PubMed
  2. Feuerstadt P, Allegretti J, Khanna S. Treatment of Clostridioides difficile : The Times They Are Changing. Am J Gastroenterol. 2025 Apr 7 Epub 2025 Apr 07
    View PubMed
  3. Berry P, Khanna S. The evolving landscape of live biotherapeutics in the treatment of Clostridioides difficile infection. Indian J Gastroenterol. 2025 Apr; 44 (2):129-141 Epub 2025 Jan 16
    View PubMed
  4. Khanna S, Seo S, Yang M, Garcia-Horton V, Gao Y, Kim HH, Ormenaj L, Guo A. Characteristics and Real-World Outcomes of Patients Treated with Fecal Microbiota, Live-jslm (RBL) for the Prevention of Recurrent Clostridioides difficile Infection. Infect Dis Ther. 2025 Apr; 14 (4):793-802 Epub 2025 Mar 21
    View PubMed
  5. Feuerstadt P, Chopra T, Knapple W, Van Hise NW, Dubberke ER, Baggott B, Guthmueller B, Bancke L, Gamborg M, Steiner TS, Van Handel D, Khanna S. PUNCH CD3-OLS: A Phase 3 Prospective Observational Cohort Study to Evaluate the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA) in Adults With Recurrent Clostridioides difficile Infection. Clin Infect Dis. 2025 Feb 5; 80 (1):43-51
    View PubMed
  6. Allman A, Friesen JN, Khanna S. 66-Year-Old Woman With Chronic Diarrhea. Mayo Clin Proc. 2025 Feb; 100 (2):340-345 Epub 2025 Jan 04
    View PubMed
  7. Allegretti JR, Kelly CR, Louie T, Fischer M, Hota S, Misra B, Van Hise NW, Yen E, Bullock JS, Silverman M, Davis I, McGill SK, Pardi DS, Orenstein R, Grinspan A, El-Nachef N, Feuerstadt P, Borody TJ, Khanna S, Budree S, Kassam Z. Safety and Tolerability of CP101, a Full-Spectrum, Oral Microbiome Therapeutic for the Prevention of Recurrent Clostridioides difficile Infection: A Phase 2 Randomized Controlled Trial. Gastroenterology. 2025 Feb; 168 (2):357-366.e3 Epub 2024 Oct 02
    View PubMed
  8. Porcari S, Mullish BH, Asnicar F, Ng SC, Zhao L, Hansen R, O'Toole PW, Raes J, Hold G, Putignani L, Hvas CL, Zeller G, Koren O, Tun H, Valles-Colomer M, Collado MC, Fischer M, Allegretti J, Iqbal T, Chassaing B, Keller J, Baunwall SM, Abreu M, Barbara G, Zhang F, Ponziani FR, Costello SP, Paramsothy S, Kao D, Kelly C, Kupcinskas J, Youngster I, Franceschi F, Khanna S, Vehreschild M, Link A, De Maio F, Pasolli E, Miguez AB, Brigidi P, Posteraro B, Scaldaferri F, Stojanovic MR, Megraud F, Malfertheiner P, Masucci L, Arumugam M, Kaakoush N, Segal E, Bajaj J, Leong R, Cryan J, Weersma RK, Knight R, Guarner F, Shanahan F, Cani PD, Elinav E, Sanguinetti M, de Vos WM, El-Omar E, Dore J, Marchesi J, Tilg H, Sokol H, Segata N, Cammarota G, Gasbarrini A, Ianiro G. International consensus statement on microbiome testing in clinical practice. Lancet Gastroenterol Hepatol. 2025 Feb; 10 (2):154-167 Epub 2024 Dec 05
    View PubMed
  9. Allegretti JR, Feuerstadt P, Knapple WL, Orenstein R, Pinton P, Sheh A, Khanna S. Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA(R)), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS. Inflamm Bowel Dis. 2025 Jan 25 [Epub ahead of print]
    View PubMed
  10. Sehgal K, Berry P, Cho J, Saffouri G, Dierkhising RA, Battaglioli E, Kashyap PC, Pardi D, Khanna S. Body mass index changes after fecal microbiota transplantation for recurrent Clostridioides difficile infection. Therap Adv Gastroenterol. 2025; 18:17562848251321121 Epub 2025 Feb 23
    View PubMed
  11. Berry P, Dhanakshirur RR, Khanna S. Utilizing large language models for gastroenterology research: a conceptual framework. Therap Adv Gastroenterol. 2025; 18:17562848251328577 Epub 2025 Apr 01
    View PubMed
  12. Coombs RA, Adkins JL, Turunen AM, Salfiti NI, Khanna S, Garg SK. Effects of Oral Anticoagulant and Antiplatelet Agents on Performance of Multitarget Colorectal Cancer Screening Test. Gastro Hep Adv. 2025; 4 (4):100610 Epub 2025 Jan 03
    View PubMed
  13. Khanna S. Microbiota restoration for recurrent Clostridioides difficile infection. Panminerva Med. 2024 Dec; 66 (4):417-426 Epub 2024 Oct 09
    View PubMed
  14. Allegretti JR, Khanna S, Mullish BH, Feuerstadt P. The Progression of Microbiome Therapeutics for the Management of Gastrointestinal Diseases and Beyond. Gastroenterology. 2024 Oct; 167 (5):885-902 Epub 2024 May 14
    View PubMed
  15. Kraft CS, Sims M, Silverman M, Louie TJ, Feuerstadt P, Huang ES, Khanna S, Berenson CS, Wang EEL, Cohen SH, Korman L, Lee C, Kelly CR, Odio A, Cook PP, Lashner B, Ramesh M, Kumar P, De A, Memisoglu A, Lombardi DA, Hasson BR, McGovern BH, von Moltke L, Pardi DS, ECOSPOR III and ECOSPOR IV investigators. Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI. Infect Dis Ther. 2024 Oct; 13 (10):2105-2121 Epub 2024 June 28
    View PubMed
  16. Kraft CS, Sims M, Silverman M, Louie TJ, Feuerstadt P, Huang ES, Khanna S, Berenson CS, Wang EEL, Cohen SH, Korman L, Lee C, Kelly CR, Odio A, Cook PP, Lashner B, Ramesh M, Kumar P, De A, Memisoglu A, Lombardi DA, Hasson BR, McGovern BH, von Moltke L, Pardi DS, ECOSPOR III and ECOSPOR IV investigators. Correction to: Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI. Infect Dis Ther. 2024 Oct; 13 (10):2209-2210
    View PubMed
  17. Tome J, Tariq R, Chelf CJ, Khanna S, Pardi DS. Effectiveness of Bile Acid Sequestrants in Microscopic Colitis and Utility of Bile Acid Testing: A Systematic Review and Meta-analysis. Am J Gastroenterol. 2024 Sep 1; 119 (9):1792-1799 Epub 2024 June 12
    View PubMed
  18. Tome J, Tariq R, Hassett LC, Khanna S, Pardi DS. Effectiveness and Safety Profile of Budesonide Maintenance in Microscopic Colitis: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis. 2024 Jul 3; 30 (7):1178-1188
    View PubMed
  19. Tariq R, Malik S, Redij R, Arunachalam S, Faubion WA Jr, Khanna S. Machine Learning-Based Prediction Models for Clostridioides difficile Infection: A Systematic Review. Clin Transl Gastroenterol. 2024 Jun 1; 15 (6):e1 Epub 2024 June 01
    View PubMed
  20. Voth E, Khanna S. Rise to the Challenge: Master the Management of Clostridioides difficile Infection. Mayo Clin Proc. 2024 Jun; 99 (6):971-979
    View PubMed
  21. Tariq R, Voth E, Khanna S. Integrating Clinical Guidelines With ChatGPT-4 Enhances Its' Skills. Mayo Clin Proc Digit Health. 2024 Jun; 2 (2):177-180 Epub 2024 Mar 28
    View PubMed
  22. Sehgal K, Yadav D, Saha S, Mara K, Grover M, Khanna S. Sex-Discordant Fecal Microbiota Transplantation for Clostridioides difficile May Increase Risk of Postinfection Irritable Bowel Syndrome. Gastroenterology. 2024 Apr; 166 (4):704-706.e2 Epub 2023 Dec 16
    View PubMed
  23. Tariq R, Loftus EV Jr, Pardi D, Khanna S. Durability and outcomes of fecal microbiota transplantation for recurrent Clostridioides difficile infection in patients with moderate to severe inflammatory bowel disease. Intest Res. 2024 Apr; 22 (2):208-212 Epub 2024 Jan 09
    View PubMed
  24. Gupta VK, Rajendraprasad S, Ozkan M, Ramachandran D, Ahmad S, Bakken JS, Laudanski K, Gajic O, Bauer B, Zec S, Freeman DW, Khanna S, Shah A, Skalski JH, Sung J, Karnatovskaia LV. Safety, feasibility, and impact on the gut microbiome of kefir administration in critically ill adults. BMC Med. 2024 Feb 20; 22 (1):80
    View PubMed
  25. Oneto C, Khanna S. Prescription Microbiome Therapeutic for Recurrent Clostridioides difficile Infection: Fecal Microbiota Live-jslm. Am J Gastroenterol. 2024 Jan 1; 119 (1S):S16-S21
    View PubMed
  26. Feuerstadt P, Allegretti JR, Dubberke ER, Guo A, Harvey A, Yang M, Garcia-Horton V, Fillbrunn M, Tillotson G, Bancke LL, LaPlante K, Garey KW, Khanna S. Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection. Infect Dis Ther. 2024 Jan; 13 (1):221-236 Epub 2024 Jan 18
    View PubMed
  27. Boyle BL, Khanna S. Fecal microbiota live - jslm (Rebyota/RBL) for management of recurrent Clostridioides difficile infection. Future Microbiol. 2024; 19 (14):1243-1251 Epub 2024 July 11
    View PubMed
  28. Berry P, Khanna S. Fecal microbiota spores, live-brpk (VOWST/VOS) for prevention of recurrent Clostridioides difficile infection. Future Microbiol. 2024; 19 (18):1519-1528 Epub 2024 Sept 25
    View PubMed
  29. Allegretti JR, Khanna S, Feuerstadt P. Practical Use of Fecal Microbiota Spores, Live BRPK for the Prevention of Recurrent Clostridioides difficile Infection. Am J Gastroenterol. 2023 Dec 1; 118 (12):2106-2108 Epub 2023 Aug 10
    View PubMed
  30. McChalicher CWJ, Lombardo MJ, Khanna S, McKenzie GJ, Halvorsen EM, Almomani S, Schuster B, Hasson BR, McGovern BH, Ege DS, Aunins JG. Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool. J Infect Dis. 2023 Nov 11; 228 (10):1452-1455
    View PubMed
  31. Berry P, Khanna S. Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies. BioDrugs. 2023 Nov; 37 (6):757-773 Epub 2023 July 26
    View PubMed
  32. Tome J, Sehgal K, Kamboj AK, Harmsen WS, Khanna S, Pardi DS. Bile Acid Sequestrants in Microscopic Colitis: Clinical Outcomes and Utility of Bile Acid Testing. Clin Gastroenterol Hepatol. 2023 Nov; 21 (12):3125-3131.e2 Epub 2023 May 10
    View PubMed
  33. Koop AH, Travers PM, Khanna S, Pardi DS, Farraye FA, Hashash JG. Fidaxomicin treatment for Clostridioides difficile infection in patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2023 Nov; 38 (11):1910-1916 Epub 2023 June 19
    View PubMed
  34. Sehgal K, Spiceland CM, Lennon RJ, Pardi DS, Khanna S. Clostridioides difficile Infection in Patients with Cirrhosis Treated for Hepatic Encephalopathy Journal of Gastrointestinal Infections. 2023; 13:26-29.
  35. Orenstein R, Hecht G, Harvey A, Tillotson G, Khanna S. Two-year durability of REBYOTA (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections. Open Forum Infect Dis. 2023 Sep; 10 (9):ofad456 Epub 2023 Sept 08
    View PubMed
  36. Feuerstadt P, Allegretti JR, Khanna S. Practical Use of RBX2660 for the Prevention of Recurrent Clostridioides difficile Infection. Am J Gastroenterol. 2023 Aug 1; 118 (8):1303-1306 Epub 2023 Jan 25
    View PubMed
  37. Tariq R, Tosh PK, Pardi DS, Khanna S. Reduction in urinary tract infections in patients treated with fecal microbiota transplantation for recurrent Clostridioides difficile infection. Eur J Clin Microbiol Infect Dis. 2023 Aug; 42 (8):1037-1041 Epub 2023 June 23
    View PubMed
  38. Khanna S, Voth E. Therapeutics for Clostridioides difficile infection: molecules and microbes. Expert Rev Gastroenterol Hepatol. 2023 Jul-Dec; 17 (9):903-911 Epub 2023 Aug 25
    View PubMed
  39. Fridkin SK, Onwubiko UN, Dube W, Robichaux C, Traenkner J, Goodenough D, Angulo FJ, Zamparo JM, Gonzalez E, Khanna S, Myers C, Dumyati G. Determinates of Clostridioides difficile infection (CDI) testing practices among inpatients with diarrhea at selected acute-care hospitals in Rochester, New York, and Atlanta, Georgia, 2020-2021. Infect Control Hosp Epidemiol. 2023 Jul; 44 (7):1085-1092 Epub 2022 Sept 14
    View PubMed
  40. Gawey BJ, Khanna S. Clostridioides difficile Infection: Landscape and Microbiome Therapeutics. Gastroenterol Hepatol (N Y). 2023 Jun; 19 (6):319-328
    View PubMed
  41. Louie T, Golan Y, Khanna S, Bobilev D, Erpelding N, Fratazzi C, Carini M, Menon R, Ruisi M, Norman JM, Faith JJ, Olle B, Li M, Silber JL, Pardi DS. VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection: A Randomized Clinical Trial. JAMA. 2023 Apr 25; 329 (16):1356-1366
    View PubMed
  42. Tariq R, Syed T, Yadav D, Prokop LJ, Singh S, Loftus EV Jr, Pardi DS, Khanna S. Outcomes of Fecal Microbiota Transplantation for C. difficile Infection in Inflammatory Bowel Disease : A Systematic Review and Meta-analysis. J Clin Gastroenterol. 2023 Mar 1; 57 (3):285-293 Epub 2023 Mar 01
    View PubMed
  43. Dubberke ER, Orenstein R, Khanna S, Guthmueller B, Lee C. Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection. Infect Dis Ther. 2023 Feb; 12 (2):703-709 Epub 2022 Dec 21
    View PubMed
  44. Sims MD, Khanna S, Feuerstadt P, Louie TJ, Kelly CR, Huang ES, Hohmann EL, Wang EEL, Oneto C, Cohen SH, Berenson CS, Korman L, Lee C, Lashner B, Kraft CS, Ramesh M, Silverman M, Pardi DS, De A, Memisoglu A, Lombardi DA, Hasson BR, McGovern BH, von Moltke L, ECOSPOR IV Investigators. Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial. JAMA Netw Open. 2023 Feb 1; 6 (2):e2255758 Epub 2023 Feb 01
    View PubMed
  45. Saha S, Pardi R, Theiler RN, Pardi DS, Khanna S. Effect of peripartum Clostridioides difficile infection on pregnancy and neonatal outcomes: an observational study. Therap Adv Gastroenterol. 2023; 16:17562848231170479 Epub 2023 Apr 27
    View PubMed
  46. Lee C, Louie T, Bancke L, Guthmueller B, Harvey A, Feuerstadt P, Khanna S, Orenstein R, Dubberke ER. Safety of fecal microbiota, live-jslm (REBYOTA()) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials. Therap Adv Gastroenterol. 2023; 16:17562848231174277 Epub 2023 June 12
    View PubMed
  47. Tariq R, Pardi DS, Khanna S. Resolution rates in clinical trials for microbiota restoration for recurrent Clostridioides difficile infection: an updated systematic review and meta-analysis. Therap Adv Gastroenterol. 2023; 16:17562848231174293 Epub 2023 May 30
    View PubMed
  48. Sehgal K, Tome J, Kamboj AK, Dierkhising RA, Pardi DS, Khanna S. The natural history of histological changes in microscopic colitis. Therap Adv Gastroenterol. 2023; 16:17562848231168237 Epub 2023 Apr 27
    View PubMed
  49. Sachan A, Khanna S, Sharma V. Publication ethics and misconducts. Indian Journal of Rheumatology. 2022 Dec; 17:334-41
  50. Perez R, Khanna S, Tillotson GS, Lett JE 2nd, Prince MA, Lattimer C. Reducing Recurrence and Complications Related to Clostridioides difficile Infection: A Panel Discussion Summary. Prof Case Manag. 2022 Nov-Dec 01; 27(6):277-287.
    View PubMed
  51. Khanna S, Assi M, Lee C, Yoho D, Louie T, Knapple W, Aguilar H, Garcia-Diaz J, Wang GP, Berry SM, Marion J, Su X, Braun T, Bancke L, Feuerstadt P. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection. Drugs. 2022 Oct; 82 (15):1527-1538 Epub 2022 Oct 26
    View PubMed
  52. Khanna S, Assi M, Lee C, Yoho D, Louie T, Knapple W, Aguilar H, Garcia-Diaz J, Wang GP, Berry SM, Marion J, Su X, Braun T, Bancke L, Feuerstadt P. Correction to: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection. Drugs. 2022 Oct; 82 (15):1539
    View PubMed
  53. Khanna S, Sims M, Louie TJ, Fischer M, LaPlante K, Allegretti J, Hasson BR, Fonte AT, McChalicher C, Ege DS, Bryant JA, Straub TJ, Ford CB, Henn MR, Wang EEL, von Moltke L, Wilcox MH. SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI). Antibiotics (Basel). 2022 Sep 10; 11 (9) Epub 2022 Sept 10
    View PubMed
  54. Sehgal K, Cifu AS, Khanna S. Treatment of Clostridioides difficile Infection. JAMA. 2022 Sep 6; 328 (9):881-882
    View PubMed
  55. Tome J, Sehgal K, Kamboj AK, Comstock B, Harmsen WS, Khanna S, Pardi DS. Budesonide Maintenance in Microscopic Colitis: Clinical Outcomes and Safety Profile From a Population-Based Study. Am J Gastroenterol. 2022 Aug 1; 117 (8):1311-1315 Epub 2022 Apr 13
    View PubMed
  56. Feuerstadt P, Aroniadis OC, Svedlund FL, Garcia M, Stong L, Boules M, Khanna S. Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection. Dig Dis Sci. 2022 Jul; 67 (7):2763-2770 Epub 2021 July 18
    View PubMed
  57. Nicholson MR, Alexander E, Ballal S, Davidovics Z, Docktor M, Dole M, Gisser JM, Goyal A, Hourigan SK, Jensen MK, Kaplan JL, Kellermayer R, Kelsen JR, Kennedy MA, Khanna S, Knackstedt ED, Lentine J, Lewis JD, Michail S, Mitchell PD, Oliva-Hemker M, Patton T, Queliza K, Sidhu S, Solomon AB, Suskind DL, Weatherly M, Werlin S, de Zoeten EF, Kahn SA, North American Society of Pediatric Gastroenterology and Nutrition Faecal Microbiota Transplantation Special Interest Group . Efficacy and Outcomes of Faecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection in Children with Inflammatory Bowel Disease. J Crohns Colitis. 2022 Jun 24; 16 (5):768-777
    View PubMed
  58. AbiMansour J, Khanna S, Sweetser S. An Important Mimicker. Gastroenterology. 2022 Jun; 162(7):1840-1843. Epub 2022 Mar 02.
    View PubMed
  59. Tome J, Sehgal K, Kamboj AK, Harmsen WS, Kammer PP, Loftus EV Jr, Tremaine WJ, Khanna S, Pardi DS. The Epidemiology of Microscopic Colitis in Olmsted County, Minnesota: Population-Based Study From 2011 to 2019. Clin Gastroenterol Hepatol. 2022 May; 20 (5):1085-1094 Epub 2021 June 30
    View PubMed
  60. Sehgal K, Zandvakili I, Tariq R, Pardi DS, Khanna S. Systematic Review and Meta-Analysis: Efficacy of Vancomycin Taper and Pulse Regimens in Clostridioides difficile Infection. Expert Rev Anti Infect Ther. 2022 Apr; 20(4):577-583. Epub 2021 Nov 01.
    View PubMed
  61. Kamboj AK, Zylberberg HM, Lane CM, Voth E, Tome J, Cuir ND, Lennon RJ, Khanna S, Lebwohl B, Pardi DS. Microscopic Colitis and Risk of Colon Adenomas: A Multicenter Retrospective Cohort Study. Clin Gastroenterol Hepatol. 2022 Apr; 20 (4):e902-e904 Epub 2021 May 29
    View PubMed
  62. Orenstein R, Dubberke ER, Khanna S, Lee CH, Yoho D, Johnson S, Hecht G, DuPont HL, Gerding DN, Blount KF, Mische S, Harvey A. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial. BMC Infect Dis. 2022 Mar 12; 22 (1):245
    View PubMed
  63. Saha S, Sehgal K, Singh S, Grover M, Pardi D, Khanna S. Postinfection Irritable Bowel Syndrome Following Clostridioides difficile Infection: A Systematic-review and Meta-analysis. J Clin Gastroenterol. 2022 Feb 1; 56 (2):e84-e93
    View PubMed
  64. Khanna S, Lett J, Lattimer C, Tillotson G. Transitions of care in Clostridioides difficile infection: a need of the hour. Therap Adv Gastroenterol. 2022; 15:17562848221078684 Epub 2022 Feb 28
    View PubMed
  65. AbiMansour J, Khanna S, Sweetser S. An important mimicker. Gastroenterology. 2022; 162 (7):1840-3
  66. Cho J, Vazquez M, Orenstein R, Loftus EV Jr, DiBaise J, Pardi DS, Khanna S. Fecal microbial transplantation is effective for postcolectomy recurrent Clostridioides difficile infection Journal of Gastrointestinal Infections. 2022; 12(1):36-40.
  67. Seekatz AM, Safdar N, Khanna S. The role of the gut microbiome in colonization resistance and recurrent Clostridioides difficile infection. Therap Adv Gastroenterol. 2022; 15:17562848221134396 Epub 2022 Nov 18
    View PubMed
  68. Choudhury A, Tariq R, Jena A, Vesely EK, Singh S, Khanna S, Sharma V. Gastrointestinal manifestations of long COVID: A systematic review and meta-analysis. Therap Adv Gastroenterol. 2022; 15:17562848221118403 Epub 2022 Aug 19
    View PubMed
  69. Venkat PG, Nguyen NH, Luo J, Qian AS, Khanna S, Singh S. Impact of recurrent hospitalization for Clostridioides difficile on longitudinal outcomes in patients with inflammatory bowel diseases: a nationally representative cohort. Therap Adv Gastroenterol. 2022; 15:17562848221141501 Epub 2022 Dec 08
    View PubMed
  70. Saha S, Mara K, Pardi DS, Khanna S. Durability of Response to Fecal Microbiota Transplantation After Exposure to Risk Factors for Recurrence in Patients With Clostridioides difficile Infection. Clin Infect Dis. 2021 Oct 5; 73 (7):e1706-e1712
    View PubMed
  71. Khanna S, Pardi DS, Jones C, Shannon WD, Gonzalez C, Blount K. RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients' Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections. Clin Infect Dis. 2021 Oct 5; 73 (7):e1613-e1620
    View PubMed
  72. Sehgal K, Khanna S. Gut microbiome and checkpoint inhibitor colitis. Intest Res. 2021 Oct; 19 (4):360-364 Epub 2020 Dec 01
    View PubMed
  73. Sehgal K, Khanna S. Gut microbiota: a target for intervention in obesity. Expert Rev Gastroenterol Hepatol. 2021 Oct; 15 (10):1169-1179 Epub 2021 Aug 06
    View PubMed
  74. Cheng YW, Alhaffar D, Saha S, Khanna S, Bohm M, Phelps E, Ghabril M, Orman E, Sashidhar S, Rogers N, Xu H, Khoruts A, Vaughn B, Kao D, Wong K, Cammarota G, Ianiro G, Dhere T, Kraft CS, Mehta N, Woodworth MH, Allegretti JR, Nativ L, Marcus J, El-Nachef N, Fischer M. Fecal Microbiota Transplantation Is Safe and Effective in Patients With Clostridioides difficile Infection and Cirrhosis. Clin Gastroenterol Hepatol. 2021 Aug; 19 (8):1627-1634 Epub 2020 July 06
    View PubMed
  75. Khanna S. My Treatment Approach to Clostridioides difficile Infection. Mayo Clin Proc. 2021 Aug; 96 (8):2192-2204 Epub 2021 June 24
    View PubMed
  76. Khanna S. Microbiota restoration for recurrent Clostridioides difficile: Getting one step closer every day! J Intern Med. 2021 Aug; 290 (2):294-309 Epub 2021 Apr 15
    View PubMed
  77. Tariq R, Saha S, Solanky D, Pardi DS, Khanna S. Predictors and Management of Failed Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. J Clin Gastroenterol. 2021 Jul 1; 55 (6):542-547
    View PubMed
  78. Khanna S. Management of Clostridioides difficile infection in patients with inflammatory bowel disease. Intest Res. 2021 Jul; 19 (3):265-274 Epub 2020 Aug 18
    View PubMed
  79. Tariq R, Hayat M, Pardi D, Khanna S. Predictors of failure after fecal microbiota transplantation for recurrent Clostridioides difficile infection: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2021 Jul; 40(7):1383-1392. Epub 2021 Jan 26.
    View PubMed
  80. McGovern BH, Ford CB, Henn MR, Pardi DS, Khanna S, Hohmann EL, O'Brien EJ, Desjardins CA, Bernardo P, Wortman JR, Lombardo MJ, Litcofsky KD, Winkler JA, McChalicher CWJ, Li SS, Tomlinson AD, Nandakumar M, Cook DN, Pomerantz RJ, Aunins JG, Trucksis M. SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis. 2021 Jun 15; 72 (12):2132-2140
    View PubMed
  81. Poylin V, Hawkins AT, Bhama AR, Boutros M, Lightner AL, Khanna S, Paquette IM, Feingold DL, Prepared by the Clinical Practice Guidelines Committee of The American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Clostridioides difficile Infection. Dis Colon Rectum. 2021 Jun 1; 64 (6):650-668
    View PubMed
  82. Khanna S, Tande A, Rubin DT, Khoruts A, Kahn SA, Pardi DS. Fecal Microbiota Transplantation for Recurrent C difficile Infection During the COVID-19 Pandemic: Experience and Recommendations. Mayo Clin Proc. 2021 Jun; 96 (6):1418-1425
    View PubMed
  83. Zylberberg HM, Kamboj AK, De Cuir N, Lane CM, Khanna S, Pardi DS, Lebwohl B. Medication use and microscopic colitis: a multicentre retrospective cohort study. Aliment Pharmacol Ther. 2021 Jun; 53 (11):1209-1215 Epub 2021 Apr 14
    View PubMed
  84. Saha S, Mara K, Pardi DS, Khanna S. Long-term Safety of Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection. Gastroenterology. 2021 May; 160 (6):1961-1969.e3 Epub 2021 Jan 11
    View PubMed
  85. Khanna S. A defined microbiome therapeutic prevents recurrent Clostridioides difficile. Lancet Gastroenterol Hepatol 2021 Apr; 6 (4):255-256 Epub 2021 Feb 23
    View PubMed
  86. Khanna S, Kraft CS. The interplay of SARS-CoV-2 and Clostridioides difficile infection. Future Microbiol. 2021 Apr; 16:439-443 Epub 2021 Apr 13
    View PubMed
  87. Janssens L, Ji H, Khanna S. 74-Year-Old Woman With Chronic Diarrhea. Mayo Clin Proc. 2021 Mar; 96 (3):770-775
    View PubMed
  88. Sehgal K, Yadav D, Khanna S. The interplay of Clostridioides difficile infection and inflammatory bowel disease. Therap Adv Gastroenterol. 2021; 14:17562848211020285 Epub 2021 May 30
    View PubMed
  89. Sehgal K, Khanna S. Gut microbiome and Clostridioides difficile infection: a closer look at the microscopic interface. Therap Adv Gastroenterol. 2021; 14:1756284821994736 Epub 2021 Feb 23
    View PubMed
  90. Saha S, Yadav D, Pardi R, Patel R, Khanna S, Pardi D. Kinetics of polymerase chain reaction positivity in patients with Clostridioides difficile infection. Therap Adv Gastroenterol. 2021; 14:17562848211050443 Epub 2021 Oct 08
    View PubMed
  91. Sehgal K, Fadel HJ, Tande AJ, Pardi DS, Khanna S. Outcomes in Patients with SARS-CoV-2 and Clostridioides difficile Coinfection. Infect Drug Resist. 2021; 14:1645-1648 Epub 2021 Apr 28
    View PubMed
  92. Yadav D, Khanna S. Safety of fecal microbiota transplantation for Clostridioides difficile infection focusing on pathobionts and SARS-CoV-2. Therap Adv Gastroenterol. 2021; 14:17562848211009694 Epub 2021 Apr 21
    View PubMed
  93. Artman C, Brumfield KD, Khanna S, Goepp J. Avian antibodies (IgY) targeting spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inhibit receptor binding and viral replication. PLoS One. 2021; 16 (5):e0252399 Epub 2021 May 28
    View PubMed
  94. Sehgal K, Khanna S. Immune response against Clostridioides difficile and translation to therapy. Therap Adv Gastroenterol. 2021; 14:17562848211014817 Epub 2021 May 07
    View PubMed
  95. Voth E, Solanky D, Loftus EV Jr, Pardi DS, Khanna S. Novel risk factors and outcomes in inflammatory bowel disease patients with Clostridioides difficile infection. Therap Adv Gastroenterol. 2021; 14:1756284821997792 Epub 2021 Mar 12
    View PubMed
  96. Tariq R, Laguio-Vila M, Tahir MW, Orenstein R, Pardi DS, Khanna S. Efficacy of oral vancomycin prophylaxis for prevention of Clostridioides difficile infection: a systematic review and meta-analysis. Therap Adv Gastroenterol. 2021; 14:1756284821994046. Epub 2021 Feb 23.
    View PubMed
  97. Kelly CR, Yen EF, Grinspan AM, Kahn SA, Atreja A, Lewis JD, Moore TA, Rubin DT, Kim AM, Serra S, Nersesova Y, Fredell L, Hunsicker D, McDonald D, Knight R, Allegretti JR, Pekow J, Absah I, Hsu R, Vincent J, Khanna S, Tangen L, Crawford CV, Mattar MC, Chen LA, Fischer M, Arsenescu RI, Feuerstadt P, Goldstein J, Kerman D, Ehrlich AC, Wu GD, Laine L. Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. Gastroenterology. 2021 Jan; 160 (1):183-192.e3 Epub 2020 Oct 01
    View PubMed
  98. Shaik L, Kashyap R, Thotamgari SR, Singh R, Khanna S. Gut-Brain Axis and its Neuro-Psychiatric Effects: A Narrative Review. Cureus. 2020 Oct 24; 12 (10):e11131
    View PubMed
  99. Khanna S. Clostridial Vaccines in the Pipeline Drugs of the Future. 2020; 45(9):633-40.
  100. Tariq R, Disbrow MB, Dibaise JK, Orenstein R, Saha S, Solanky D, Loftus EV, Pardi DS, Khanna S. Efficacy of Fecal Microbiota Transplantation for Recurrent C. Difficile Infection in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020 Aug 20; 26 (9):1415-1420
    View PubMed
  101. Tariq R, Saha S, Furqan F, Hassett L, Pardi D, Khanna S. Prevalence and Mortality of COVID-19 Patients With Gastrointestinal Symptoms: A Systematic Review and Meta-analysis. Mayo Clin Proc. 2020 Aug; 95 (8):1632-1648 Epub 2020 June 10
    View PubMed
  102. Khanna S, Pardi D. Fecal Microbiota Transplantation for Recurrent Clostridioides difficile infection: The COVID-19 Era. Am J Gastroenterol. 2020 Jul; 115 (7):971-974
    View PubMed
  103. Voth E, Khanna S. Fecal microbiota transplantation for treatment of patients with recurrent Clostridioides difficile infection. Expert Rev Anti Infect Ther. 2020 Jul; 18 (7):669-676 Epub 2020 Apr 12
    View PubMed
  104. Khanna S. Fecal transplant clinical trials for Clostridioides difficile: an interview with Sahil Khanna. Future Microbiol 2020 Jun; 15:709-712 Epub 2020 July 17
    View PubMed
  105. Garg SK, Obaitan I, Sarvepalli S, Anugwom CM, Pardi DS, Khanna S. Clostridium difficile Infection in the Emergency Department. J Clin Gastroenterol. 2020 Apr; 54(4):350-355.
    View PubMed
  106. Cho JM, Pardi DS, Khanna S. Update on Treatment of Clostridioides difficile Infection. Mayo Clin Proc. 2020 Apr; 95 (4):758-769
    View PubMed
  107. Nicholson MR, Mitchell PD, Alexander E, Ballal S, Bartlett M, Becker P, Davidovics Z, Docktor M, Dole M, Felix G, Gisser J, Hourigan SK, Jensen MK, Kaplan JL, Kelsen J, Kennedy M, Khanna S, Knackstedt E, Leier M, Lewis J, Lodarek A, Michail S, Oliva-Hemker M, Patton T, Queliza K, Russell GH, Singh N, Solomon A, Suskind DL, Werlin S, Kellermayer R, Kahn SA. Efficacy of Fecal Microbiota Transplantation for Clostridium difficile Infection in Children. Clin Gastroenterol Hepatol. 2020 Mar; 18 (3):612-619.e1 Epub 2019 Apr 19
    View PubMed
  108. Gupta A, Saha S, Khanna S. Therapies to modulate gut microbiota: Past, present and future. World J Gastroenterol. 2020 Feb 28; 26 (8):777-788
    View PubMed
  109. von Itzstein MS, Gupta A, Kernstine KH, Mara KC, Khanna S, Gerber DE. Increased reporting but decreased mortality associated with adverse events in patients undergoing lung cancer surgery: Competing forces in an era of heightened focus on care quality? PLoS One. 2020; 15 (4):e0231258 Epub 2020 Apr 09
    View PubMed
  110. Saha S, Pardi R, Theiler RN, Pardi DS, Khanna S. Incidence of Clostridioides difficile infection in peripartum women: a retrospective cohort study. Therap Adv Gastroenterol. 2020; 13:1756284820942621. Epub 2020 Jul 27.
    View PubMed
  111. Podboy AJ, Lavey C, Mara K, Geno D, Khana S, Ravi K, Katzka D, Alexander J. Eosinophilic Esophagitis Is Rarely Continually Symptomatic 10 Years After an Initial Treatment Course in Adults. Dig Dis Sci. 2019 Dec; 64 (12):3568-3578 Epub 2019 May 07
    View PubMed
  112. Park SH, Al-Bawardy B, Aniwan S, Kane SV, Coelho-Prabhu N, Papadakis KA, Kisiel JB, Bruining DH, Faubion WA, Raffals LE, Pardi DS, Tremaine WJ, Stephens MC, Tung J, Khanna S, Willrich, Loftus EV. Distinct cutoff values of adalimumab trough levels are associated with different therapeutic outcomes in patients with inflammatory bowel disease. Crohn's & Colitis 360. 2019; 1(3):otz047.
  113. von Itzstein MS, Gupta A, Mara KC, Khanna S, Gerber DE. Increasing Numbers and Reported Adverse Events in Patients with Lung Cancer Undergoing Inpatient Lung Biopsies: A Population-Based Analysis. Lung. 2019 Oct; 197 (5):593-599 Epub 2019 July 31
    View PubMed
  114. Saha S, Tariq R, Tosh PK, Pardi DS, Khanna S. Faecal microbiota transplantation for eradicating carriage of multidrug-resistant organisms: a systematic review. Clin Microbiol Infect. 2019 Aug; 25 (8):958-963 Epub 2019 Apr 12
    View PubMed
  115. Khanna S, Gerding DN. Current and future trends in clostridioides (clostridium) difficile infection management. Anaerobe. 2019 Aug; 58:95-102 Epub 2019 May 01
    View PubMed
  116. Saha S, Kapoor S, Tariq R, Schuetz AN, Tosh PK, Pardi DS, Khanna S. Increasing antibiotic resistance in Clostridioides difficile: A systematic review and meta-analysis. Anaerobe. 2019 Aug; 58:35-46. Epub 2019 Jul 19.
    View PubMed
  117. Cho JM, Pestana L, Pardi R, Pardi DS, Khanna S. Fecal microbiota transplant via colonoscopy may be preferred due to intraprocedure findings. Intest Res. 2019 Jul; 17 (3):434-437 Epub 2019 May 31
    View PubMed
  118. Khanna S. Ridinilazole antibacterial drug treatment of clostridioides difficile infection Drugs Of The Future. 2019 May; 44 (5):349-55
  119. Tariq R, Pardi DS, Bartlett MG, Khanna S. Low Cure Rates in Controlled Trials of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis. Clin Infect Dis. 2019 Apr 08; 68(8):1351-1358.
    View PubMed
  120. Ball S, Brown TJ, Das A, Khera R, Khanna S, Gupta A. Effect of Neutropenic Diet on Infection Rates in Cancer Patients With Neutropenia: A Meta-analysis of Randomized Controlled Trials. Am J Clin Oncol. 2019 Mar; 42 (3):270-274
    View PubMed
  121. Solanky D, Pardi DS, Loftus EV, Khanna S. Colon Surgery Risk With Corticosteroids Versus Immunomodulators or Biologics in Inflammatory Bowel Disease Patients With Clostridium difficile Infection. Inflamm Bowel Dis. 2019 Feb 21; 25 (3):610-619
    View PubMed
  122. Cheng YW, Phelps E, Ganapini V, Khan N, Ouyang F, Xu H, Khanna S, Tariq R, Friedman-Moraco RJ, Woodworth MH, Dhere T, Kraft CS, Kao D, Smith J, Le L, El-Nachef N, Kaur N, Kowsika S, Ehrlich A, Smith M, Safdar N, Misch EA, Allegretti JR, Flynn A, Kassam Z, Sharfuddin A, Vuppalanchi R, Fischer M. Fecal microbiota transplantation for the treatment of recurrent and severe Clostridium difficile infection in solid organ transplant recipients: A multicenter experience. Am J Transplant. 2019 Feb; 19 (2):501-511 Epub 2018 Aug 31
    View PubMed
  123. Tariq R, Law CCY, Khanna S, Murthy S, McCurdy JD. The Impact of Clostridium difficile Infection on Mortality in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2019 Feb; 53(2):127-133.
    View PubMed
  124. Sartelli M, Di Bella S, McFarland LV, Khanna S, Furuya-Kanamori L, Abuzeid N, Abu-Zidan FM, Ansaloni L, Augustin G, Bala M, Ben-Ishay O, Biffl WL, Brecher SM, Camacho-Ortiz A, Cainzos MA, Chan S, Cherry-Bukowiec JR, Clanton J, Coccolini F, Cocuz ME, Coimbra R, Cortese F, Cui Y, Czepiel J, Demetrashvili Z, Di Carlo I, Di Saverio S, Dumitru IM, Eckmann C, Eiland EH, Forrester JD, Fraga GP, Frossard JL, Fry DE, Galeiras R, Ghnnam W, Gomes CA, Griffiths EA, Guirao X, Ahmed MH, Herzog T, Kim JI, Iqbal T, Isik A, Itani KMF, Labricciosa FM, Lee YY, Juang P, Karamarkovic A, Kim PK, Kluger Y, Leppaniemi A, Lohsiriwat V, Machain GM, Marwah S, Mazuski JE, Metan G, Moore EE, Moore FA, Ordonez CA, Pagani L, Petrosillo N, Portela F, Rasa K, Rems M, Sakakushev BE, Segovia-Lohse H, Sganga G, Shelat VG, Spigaglia P, Tattevin P, Trana C, Urbanek L, Ulrych J, Viale P, Baiocchi GL, Catena F. 2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients. World J Emerg Surg. 2019; 14:8 Epub 2019 Feb 28
    View PubMed
  125. Saha S, Khanna S. Management of Clostridioides difficile colitis: insights for the gastroenterologist. Therap Adv Gastroenterol. 2019; 12:1756284819847651 Epub 2019 May 06
    View PubMed
  126. Battaglioli EJ, Hale VL, Chen J, Jeraldo P, Ruiz-Mojica C, Schmidt BA, Rekdal VM, Till LM, Huq L, Smits SA, Moor WJ, Jones-Hall Y, Smyrk T, Khanna S, Pardi DS, Grover M, Patel R, Chia N, Nelson H, Sonnenburg JL, Farrugia G, Kashyap PC. Clostridioides difficile uses amino acids associated with gut microbial dysbiosis in a subset of patients with diarrhea. Sci Transl Med. 2018 Oct 24; 10 (464)
    View PubMed
  127. Dubberke ER, Lee CH, Orenstein R, Khanna S, Hecht G, Gerding DN. Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection. Clin Infect Dis. 2018 Sep 28; 67 (8):1198-1204
    View PubMed
  128. Gupta A, Cifu AS, Khanna S. Diagnosis and Treatment of Clostridium difficile Infection. JAMA. 2018 Sep 11; 320 (10):1031-1032
    View PubMed
  129. Khanna S. Rbx-2660. microbiota restoration therapy, treatment of recurrent clostridium difficile infection Drugs Of The Future. 2018 Jun; 43 (6):389-94
  130. Charilaou P, Devani K, John F, Kanna S, Ahlawat S, Young M, Khanna S, Reddy C. Acute kidney injury impact on inpatient mortality in Clostridium difficile infection: A national propensity-matched study. J Gastroenterol Hepatol. 2018 Jun; 33 (6):1227-1233 Epub 2018 Feb 26
    View PubMed
  131. Sacco KA, Pongdee T, Binnicker MJ, Espy M, Pardi D, Khanna S, Joshi AY. Presence of immune deficiency increases the risk of hospitalization in patients with norovirus infection. Diagn Microbiol Infect Dis. 2018 Apr; 90 (4):300-306 Epub 2017 Dec 05
    View PubMed
  132. Hanada Y, Khanna S, Loftus EV Jr, Raffals LE, Pardi DS. Non-Clostridium difficile Bacterial Infections Are Rare in Patients With Flares of Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2018 Apr; 16 (4):528-533 Epub 2017 Oct 14
    View PubMed
  133. Cho J, Seville MT, Khanna S, Pardi DS, Sampathkumar P, Kashyap PC. Screening for Clostridium difficile colonization on admission to a hematopoietic stem cell transplant unit may reduce hospital-acquired C difficile infection. Am J Infect Control. 2018 Apr; 46 (4):459-461 Epub 2017 Nov 21
    View PubMed
  134. Gupta A, Das A, Tariq R, Bhulani N, Premnath N, Solanky D, Frank RD, Johnson D, Khanna S, Beg MS. Trends in Outcomes of Patients With Metastatic Cancer Undergoing Intubation and Mechanical Ventilation: Results of the National Hospital Discharge Survey. J Natl Compr Canc Netw. 2018 Mar; 16(3):286-292.
    View PubMed
  135. Tariq R, Cho J, Kapoor S, Orenstein R, Singh S, Pardi DS, Khanna S. Low Risk of Primary Clostridium difficile Infection With Tetracyclines: A Systematic Review and Metaanalysis. Clin Infect Dis. 2018 Feb 01; 66(4):514-522.
    View PubMed
  136. Jansson-Knodell CL, Khanna S. The Role of Anchoring in Working Up Diarrhea: A Practical Teaching Case. Gastroenterology. 2018 Feb; 154 (3):498-499 Epub 2017 Oct 12
    View PubMed
  137. Tariq R, Weatherly R, Kammer P, Pardi DS, Khanna S. Donor Screening Experience for Fecal Microbiota Transplantation in Patients With Recurrent C. difficile Infection. J Clin Gastroenterol. 2018 Feb; 52(2):146-150.
    View PubMed
  138. Spiceland CM, Khanna S, Pardi DS. Outcomes With Fidaxomicin Therapy in Clostridium difficile Infection. J Clin Gastroenterol. 2018 Feb; 52 (2):151-154
    View PubMed
  139. Tariq R, Mukhija D, Gupta A, Singh S, Pardi DS, Khanna S. Statin use and the risk of Clostridium difficile infection: a systematic review with meta-analysis. Infect Drug Resist. 2018; 11:405-416 Epub 2018 Mar 13
    View PubMed
  140. Khanna S. Microbiota Replacement Therapies: Innovation in Gastrointestinal Care. Clin Pharmacol Ther. 2018 Jan; 103 (1):102-111 Epub 2017 Nov 14
    View PubMed
  141. Daley P, Louie T, Lutz JE, Khanna S, Stoutenburgh U, Jin M, Adedoyin A, Chesnel L, Guris D, Larson KB, Murata Y. Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial. J Antimicrob Chemother. 2017 Dec 1; 72 (12):3462-3470
    View PubMed
  142. Khanna S. Microbiota restoration therapy in infectious diseases Drugs Of The Future. 2017 Dec; 42 (12):757-66
  143. Saffouri G, Gupta A, Loftus EV Jr, Baddour LM, Pardi DS, Khanna S. The incidence and outcomes from Clostridium difficile infection in hospitalized adults with inflammatory bowel disease. Scand J Gastroenterol. 2017 Nov; 52 (11):1240-1247 Epub 2017 Aug 06
    View PubMed
  144. Hefazi M, Patnaik MM, Hogan WJ, Litzow MR, Pardi DS, Khanna S. Safety and Efficacy of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection in Patients With Cancer Treated With Cytotoxic Chemotherapy: A Single-Institution Retrospective Case Series. Mayo Clin Proc. 2017 Nov; 92 (11):1617-1624 Epub 2017 Nov 01
    View PubMed
  145. Tariq R, Pardi DS, Tosh PK, Walker RC, Razonable RR, Khanna S. Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection Reduces Recurrent Urinary Tract Infection Frequency. Clin Infect Dis. 2017 Oct 30; 65(10):1745-1747.
    View PubMed
  146. Khanna S, Raffals LE. The Microbiome in Crohn's Disease: Role in Pathogenesis and Role of Microbiome Replacement Therapies. Gastroenterol Clin North Am. 2017 Sep; 46 (3):481-492 Epub 2017 July 19
    View PubMed
  147. Tariq R, Weatherly RM, Kammer PP, Pardi DS, Khanna S. Experience and Outcomes at a Specialized Clostridium difficile Clinical Practice. Mayo Clin Proc Innov Qual Outcomes. 2017 Jul; 1(1):49-56. Epub 2017 May 19.
    View PubMed
  148. Lightner AL, Tse CS, Quinn K, Bergquist JR, Enders F, Pendegraft R, Khanna S, Raffals L. Preoperative Clostridium difficile Infection Does Not Affect Pouch Outcomes in Patients with Ulcerative Colitis Who Undergo Ileal Pouch-anal Anastomosis. Inflamm Bowel Dis. 2017 Jul; 23 (7):1195-1201
    View PubMed
  149. Tariq R, Singh S, Gupta A, Pardi DS, Khanna S. Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis. JAMA Intern Med. 2017 Jun 01; 177(6):784-791.
    View PubMed
  150. Khanna S, Vazquez-Baeza Y, Gonzalez A, Weiss S, Schmidt B, Muniz-Pedrogo DA, Rainey JF 3rd, Kammer P, Nelson H, Sadowsky M, Khoruts A, Farrugia SL, Knight R, Pardi DS, Kashyap PC. Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease. Microbiome. 2017 May 15; 5 (1):55
    View PubMed
  151. Law CC, Tariq R, Khanna S, Murthy S, McCurdy JD. Systematic review with meta-analysis: the impact of Clostridium difficile infection on the short- and long-term risks of colectomy in inflammatory bowel disease. Aliment Pharmacol Ther. 2017 Apr; 45 (8):1011-1020 Epub 2017 Feb 16
    View PubMed
  152. Gupta A, Tariq R, Frank RD, Jean GW, Beg MS, Pardi DS, Johnson DH, Khanna S. Trends in the Incidence and Outcomes of Hospitalized Cancer Patients With Clostridium difficile Infection: A Nationwide Analysis. J Natl Compr Canc Netw. 2017 Apr; 15(4):466-472.
    View PubMed
  153. Khanna S, Shin A, Kelly CP. Management of Clostridium difficile Infection in Inflammatory Bowel Disease: Expert Review from the Clinical Practice Updates Committee of the AGA Institute. Clin Gastroenterol Hepatol. 2017 Feb; 15 (2):166-174
    View PubMed
  154. Tariq R, Khanna S. Clostridium difficile infection: Updates in management. Indian J Gastroenterol. 2017 Jan; 36(1):3-10. Epub 2016 Dec 20.
    View PubMed
  155. Malikowski T, Khanna S, Pardi DS. Fecal microbiota transplantation for gastrointestinal disorders. Curr Opin Gastroenterol. 2017 Jan; 33 (1):8-13
    View PubMed
  156. Gupta A, Khanna S. Repeat Clostridium difficile Testing. JAMA. 2016 Dec 13; 316 (22):2422-2423
    View PubMed
  157. McCurdy JD, Enders FT, Khanna S, Bruining DH, Jones A, Killian JM, Tariq R, Smyrk TC, Loftus EV Jr. Increased Rates of Clostridium difficile Infection and Poor Outcomes in Patients with IBD with Cytomegalovirus. Inflamm Bowel Dis. 2016 Nov; 22(11):2688-2693.
    View PubMed
  158. Gupta A, Pardi DS, Baddour LM, Khanna S. Outcomes in children with Clostridium difficile infection: results from a nationwide survey. Gastroenterol Rep (Oxf). 2016 Nov; 4 (4):293-298 Epub 2016 Apr 14
    View PubMed
  159. Khanna S, Pardi DS. Clinical implications of antibiotic impact on gastrointestinal microbiota and Clostridium difficile infection. Expert Rev Gastroenterol Hepatol. 2016 Oct; 10 (10):1145-1152 Epub 2016 Mar 16
    View PubMed
  160. Khanna S, Montassier E, Schmidt B, Patel R, Knights D, Pardi DS, Kashyap P. Gut microbiome predictors of treatment response and recurrence in primary Clostridium difficile infection. Aliment Pharmacol Ther. 2016 Oct; 44 (7):715-727 Epub 2016 Aug 02
    View PubMed
  161. Wadhwa A, Al Nahhas MF, Dierkhising RA, Patel R, Kashyap P, Pardi DS, Khanna S, Grover M. High risk of post-infectious irritable bowel syndrome in patients with Clostridium difficile infection. Aliment Pharmacol Ther. 2016 Sep; 44 (6):576-82 Epub 2016 July 22
    View PubMed
  162. Meehan AM, Tariq R, Khanna S. Challenges in management of recurrent and refractory Clostridium difficile infection World J Clin Infect Dis. 2016; 6(3):28-36.
  163. Khanna S, Gupta A, Baddour LM, Pardi DS. Epidemiology, outcomes, and predictors of mortality in hospitalized adults with Clostridium difficile infection. Intern Emerg Med. 2016 Aug; 11 (5):657-65 Epub 2015 Dec 22
    View PubMed
  164. Khanna S, Pardi DS, Kelly CR, Kraft CS, Dhere T, Henn MR, Lombardo MJ, Vulic M, Ohsumi T, Winkler J, Pindar C, McGovern BH, Pomerantz RJ, Aunins JG, Cook DN, Hohmann EL. A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection. J Infect Dis. 2016 Jul 15; 214 (2):173-81 Epub 2016 Feb 08
    View PubMed
  165. Martinez Ugarte ML, Lightner AL, Colibaseanu D, Khanna S, Pardi DS, Dozois EJ, Mathis KL. Clostridium difficile infection after restorative proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis. Colorectal Dis. 2016 May; 18 (5):O154-7
    View PubMed
  166. Gupta A, Mehta A, Khanna S. Palmar-plantar erythrodysesthesia. BMJ Case Rep. 2015 Sep 10; 2015 Epub 2015 Sept 10
    View PubMed
  167. Gupta A, De Felice KM, Loftus EV Jr, Khanna S. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther. 2015 Aug; 42 (4):406-17 Epub 2015 June 15
    View PubMed
  168. De Felice KM, Gupta A, Rakshit S, Khanna S, Kottschade LA, Finnes HD, Papadakis KA, Loftus EV Jr, Raffals LE, Markovic SN. Ipilimumab-induced colitis in patients with metastatic melanoma. Melanoma Res. 2015 Aug; 25 (4):321-7
    View PubMed
  169. Gupta A, Khanna S. Ipilimumab-associated colitis or refractory Clostridium difficile infection? BMJ Case Rep. 2015 Jul 7; 2015 Epub 2015 July 07
    View PubMed
  170. Sartelli M, Malangoni MA, Abu-Zidan FM, Griffiths EA, Di Bella S, McFarland LV, Eltringham I, Shelat VG, Velmahos GC, Kelly CP, Khanna S, Abdelsattar ZM, Alrahmani L, Ansaloni L, Augustin G, Bala M, Barbut F, Ben-Ishay O, Bhangu A, Biffl WL, Brecher SM, Camacho-Ortiz A, Cainzos MA, Canterbury LA, Catena F, Chan S, Cherry-Bukowiec JR, Clanton J, Coccolini F, Cocuz ME, Coimbra R, Cook CH, Cui Y, Czepiel J, Das K, Demetrashvili Z, Di Carlo I, Di Saverio S, Dumitru IM, Eckert C, Eckmann C, Eiland EH, Enani MA, Faro M, Ferrada P, Forrester JD, Fraga GP, Frossard JL, Galeiras R, Ghnnam W, Gomes CA, Gorrepati V, Ahmed MH, Herzog T, Humphrey F, Kim JI, Isik A, Ivatury R, Lee YY, Juang P, Furuya-Kanamori L, Karamarkovic A, Kim PK, Kluger Y, Ko WC, LaBarbera FD, Lee JG, Leppaniemi A, Lohsiriwat V, Marwah S, Mazuski JE, Metan G, Moore EE, Moore FA, Nord CE, Ordonez CA, Junior GA, Petrosillo N, Portela F, Puri BK, Ray A, Raza M, Rems M, Sakakushev BE, Sganga G, Spigaglia P, Stewart DB, Tattevin P, Timsit JF, To KB, Trana C, Uhl W, Urbanek L, van Goor H, Vassallo A, Zahar JR, Caproli E, Viale P. WSES guidelines for management of Clostridium difficile infection in surgical patients. World J Emerg Surg. 2015; 10:38 Epub 2015 Aug 20
    View PubMed
  171. Gupta A, Patel R, Baddour LM, Pardi DS, Khanna S. Extraintestinal Clostridium difficile infections: a single-center experience. Mayo Clin Proc. 2014 Nov; 89 (11):1525-36 Epub 2014 Sept 20
    View PubMed
  172. Xiong Y, Svingen PA, Sarmento OO, Smyrk TC, Dave M, Khanna S, Lomberk GA, Urrutia RA, Faubion WA Jr. Differential coupling of KLF10 to Sin3-HDAC and PCAF regulates the inducibility of the FOXP3 gene. Am J Physiol Regul Integr Comp Physiol. 2014 Sep 15; 307 (6):R608-20 Epub 2014 June 18
    View PubMed
  173. Shivashankar R, Khanna S, Kammer PP, Scott Harmsen W, Zinsmeister AR, Baddour LM, Pardi DS. Clinical predictors of recurrent Clostridium difficile infection in out-patients. Aliment Pharmacol Ther. 2014 Sep; 40 (5):518-22 Epub 2014 July 10
    View PubMed
  174. Johnson DH, Khanna S, Smyrk TC, Loftus EV Jr, Anderson KS, Mahoney DW, Ahlquist DA, Kisiel JB. Detection rate and outcome of colonic serrated epithelial changes in patients with ulcerative colitis or Crohn's colitis. Aliment Pharmacol Ther. 2014 Jun; 39 (12):1408-17 Epub 2014 Apr 30
    View PubMed
  175. Saffouri G, Khanna S, Estes L, Pardi D. Outcomes from rectal vancomycin therapy in patients with Clostridium difficile infection. Am J Gastroenterol 2014 Jun; 109 (6):924-5
    View PubMed
  176. Gentile NM, Khanna S, Loftus EV Jr, Smyrk TC, Tremaine WJ, Harmsen WS, Zinsmeister AR, Kammer PP, Pardi DS. The epidemiology of microscopic colitis in Olmsted County from 2002 to 2010: a population-based study. Clin Gastroenterol Hepatol. 2014 May; 12 (5):838-42 Epub 2013 Oct 09
    View PubMed
  177. Gupta A, Khanna S. Proton pump inhibitors and C. difficile Infection: A perspective JSM Gastroenterol Hepatol. 2014; 2(3):1020.
  178. Khanna S, Pardi DS. Clostridium difficile infection: management strategies for a difficult disease. Therap Adv Gastroenterol. 2014 Mar; 7 (2):72-86
    View PubMed
  179. Gupta A, Khanna S. Community-acquired Clostridium difficile infection: an increasing public health threat. Infect Drug Resist. 2014; 7:63-72 Epub 2014 Mar 17
    View PubMed
  180. Khanna S, Tosh PK. A clinician's primer on the role of the microbiome in human health and disease. Mayo Clin Proc. 2014 Jan; 89 (1):107-14
    View PubMed
  181. Shivashankar R, Khanna S, Kammer PP, Harmsen WS, Zinsmeister AR, Baddour LM, Pardi DS. Clinical factors associated with development of severe-complicated Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013 Nov; 11 (11):1466-71 Epub 2013 May 20
    View PubMed
  182. Nadkarni NA, Khanna S, Vege SS. Splanchnic venous thrombosis and pancreatitis. Pancreas. 2013 Aug; 42 (6):924-31
    View PubMed
  183. Khanna S, Keddis MT, Noheria A, Baddour LM, Pardi DS. Acute kidney injury is an independent marker of severity in Clostridium difficile infection: a nationwide survey. J Clin Gastroenterol. 2013 Jul; 47(6):481-4.
    View PubMed
  184. Singh S, Khanna S, Pardi DS, Loftus EV Jr, Talwalkar JA. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2013 Jul; 19 (8):1631-8
    View PubMed
  185. Khanna S, Baddour LM, Huskins WC, Kammer PP, Faubion WA, Zinsmeister AR, Harmsen WS, Pardi DS. The epidemiology of Clostridium difficile infection in children: a population-based study. Clin Infect Dis. 2013 May; 56 (10):1401-6 Epub 2013 Feb 13
    View PubMed
  186. Khanna S, Baddour LM, Dibaise JK, Pardi DS. Appendectomy is not associated with adverse outcomes in clostridium difficile infection: a population-based study. Am J Gastroenterol 2013 Apr; 108 (4):626-7
    View PubMed
  187. Gentile NM, Abdalla AA, Khanna S, Smyrk TC, Tremaine WJ, Faubion WA, Kammer PP, Sandborn WJ, Loftus EV Jr, Pardi DS. Outcomes of patients with microscopic colitis treated with corticosteroids: a population-based study. Am J Gastroenterol. 2013 Feb; 108 (2):256-9 Epub 2013 Jan 08
    View PubMed
  188. Rahman MK, Offord CP, Khanna S, Ford GC, Perrson XM, Svingen PA, Xiong Y, Bajzer Z, Faubion WA Jr. Regulatory T cell kinetics in the peripheral blood of patients with Crohn's disease. Hum Immunol. 2013 Feb; 74 (2):145-50 Epub 2012 Nov 05
    View PubMed
  189. Gronwall C, Chen Y, Vas J, Khanna S, Thiel S, Corr MP, Kono DH, Silverman GJ. MAPK phosphatase-1 is required for regulatory natural autoantibody mediated inhibition of TLR responses. Proc Natl Acad Sci USA. 2012 Nov 27; 109(48):19745-50.
    View PubMed
  190. Khanna S, Pardi DS. Clostridium difficile infection: new insights into management. Mayo Clin Proc. 2012 Nov; 87 (11):1106-17
    View PubMed
  191. Keddis MT, Khanna S, Noheria A, Baddour LM, Pardi DS, Qian Q. Clostridium difficile infection in patients with chronic kidney disease. Mayo Clin Proc. 2012 Nov; 87 (11):1046-53
    View PubMed
  192. Khanna S, Pardi DS, Rosenblatt JE, Patel R, Kammer PP, Baddour LM. An evaluation of repeat stool testing for Clostridium difficile infection by polymerase chain reaction. J Clin Gastroenterol. 2012 Nov-Dec; 46 (10):846-9
    View PubMed
  193. Xiong Y, Khanna S, Grzenda AL, Sarmento OF, Svingen PA, Lomberk GA, Urrutia RA, Faubion WA Jr. Polycomb antagonizes p300/CREB-binding protein-associated factor to silence FOXP3 in a Kruppel-like factor-dependent manner. J Biol Chem. 2012 Oct 5; 287 (41):34372-85 Epub 2012 Aug 15
    View PubMed
  194. Khanna S, Aronson SL, Kammer PP, Baddour LM, Pardi DS. Gastric acid suppression and outcomes in Clostridium difficile infection: a population-based study. Mayo Clin Proc. 2012 Jul; 87 (7):636-42
    View PubMed
  195. Khanna S, Pardi DS, Aronson SL, Kammer PP, Baddour LM. Outcomes in community-acquired Clostridium difficile infection. Aliment Pharmacol Ther. 2012 Mar; 35 (5):613-8 Epub 2012 Jan 10
    View PubMed
  196. Mikhalkova D, Khanna S, Vaidya R, Sethi S, Hogan MC. Epstein-Barr virus-associated nephrotic syndrome. Clin Kidney J. 2012 Feb; 5 (1):50-2
    View PubMed
  197. Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St Sauver JL, Harmsen WS, Zinsmeister AR. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol. 2012 Jan; 107 (1):89-95 Epub 2011 Nov 22
    View PubMed
  198. Khanna S, Sedlack RE, Mangan TF. An unusual case of SIADH. Gastroenterol Hepatol (N Y). 2011 Mar; 7 (3):191-3
    View PubMed
  199. Khanna S, Arora AS. An UninSTENTed Consequence - Fellow's Corner Practical Gastroenterology. Jan 2011; 35(1):38-40.
  200. Noheria A, Khanna S, West CP. 37-year-old woman with palpitations and fatigue. Mayo Clin Proc. 2011 Jan; 86 (1):75-8
    View PubMed
  201. Khanna S, Pardi DS. The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol. 2010 Aug; 4 (4):409-16
    View PubMed
  202. Khanna S, Noheria A, Rohren CH. 52-year-old woman with dysphagia. Mayo Clin Proc. 2010 Aug; 85 (8):760-3
    View PubMed
  203. Khanna S, Reed AM. Immunopathogenesis of juvenile dermatomyositis. Muscle Nerve. 2010 May; 41(5):581-92.
    View PubMed
  204. Chen Y, Khanna S, Goodyear CS, Park YB, Raz E, Thiel S, Gronwall C, Vas J, Boyle DL, Corr M, Kono DH, Silverman GJ. Regulation of dendritic cells and macrophages by an anti-apoptotic cell natural antibody that suppresses TLR responses and inhibits inflammatory arthritis. J Immunol. 2009 Jul 15; 183(2):1346-59. Epub 2009 Jun 29.
    View PubMed
  205. Silverman GJ, Khanna S. B cell modulation in rheumatology. Curr Opin Pharmacol. 2007 Aug; 7(4):426-33. Epub 2007 Jul 10.
    View PubMed
  206. Khanna S, Pal H, Pandey RM, Handa R. The relationship between disease activity and quality of life in systemic lupus erythematosus. Rheumatology (Oxford). 2004 Dec; 43(12):1536-40. Epub 2004 Sep 01.
    View PubMed
PST-20217057